fig3
![Do elderly NSCLC stage IV patients benefit from chemotherapy as well as younger? An analysis from clinical practice date](https://image.oaes.cc/2a601715-4a9c-49a7-8ef5-8fb79aa25ad8/1437.fig.3.png)
Figure 3. Comparison: treated versus untreated young patients.EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor; PS: performance status
Figure 3. Comparison: treated versus untreated young patients.EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor; PS: performance status
All published articles are preserved here permanently:
https://www.portico.org/publishers/oae/